New erythropoiesis-stimulating agents and new iron formulations

Contributions to Nephrology

Volumn 171, Issue , 2011, Pages 255-260

  Locatelli, Francesco ^a   Del Vecchio, Lucia ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; IRON;

ANEMIA; ARTICLE; CHRONIC DISEASE; HUMAN; KIDNEY DISEASE;

ANEMIA; CHRONIC DISEASE; HEMATINICS; HUMANS; IRON; KIDNEY DISEASES;

EID: 84906835991     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000327328     Document Type: Article

References (29)

1. Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK, Dower WJ: Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996; 273:458-464.
2. Fan Q, Leuther KK, Holmes CP, Fong KL, Zhang J, Velkovska S, Chen MJ, Mortensen RB, Leu K, Green JM, Schatz PJ, Woodburn KW: Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 2006;34:1303-1311. (Pubitemid 44389891)
3. Woodburn KW, Fan Q, Winslow S, Chen MJ, Mortensen RB, Casadevall N, Stead RB, Schatz PJ: Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol 2007;35: 1201-1208. (Pubitemid 47088782)
4. Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M, Eckardt KU: A peptide- based erythropoietin- receptor agonist for pure red- cell aplasia. N Engl J Med 2009;361:1848-1855.
5. Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW, Schatz PJ, Okamoto DM, Naso R, Duliege AM: Evaluation of the safety and pharmacodynamics of hematide, a novel erythropoietic agent, in a phase 1, double- blind, placebocontrolled, dose- escalation study in healthy volunteers. Blood 2006; 108:1830-1834. (Pubitemid 44394989)
6. Pickering LM, Cwiertka K, Jassem J, et al: Hematide, a synthetic peptidebased erythropoiesis stimulating agent (ESA), assessed for correction of anemia in oncology patients receiving chemotherapy. Blood 2006;108:378a- 378a.
7. Wiecek A, Tucker B, Nowicki M, et al: Comparison of monthly dosing schemes using HematideTM, a synthetic peptide- based erythropoiesis stimulating agent (ESA), to correct anemia in patients with chronic kidney disease (CKD) not on dialysis. Presentation, 40th Renal Week Am Soc Nephrol, San Francisco, 31 October to 5 November 2007.
8. Besarab A, Zeig S, Geronemus R, et al: Comparison of monthly dosing schemes using HematideTM, a synthetic peptide- based erythropoiesis stimulating agent (ESA), to maintain hemoglobin (Hb) in hemodialysis (HD) patients previously treated with epoetin alfa (EPO). Presentation, 40th Renal Week Am Soc Nephrol, San Francisco, 31 October to 5 November 2007.
9. Covic A, Ardelean L, Manuelyan L, et al: A phase 2, open- label, multicenter, dose finding study of the safety, pharmacodynamics, and pharmacokinetics of HematideTM for the maintenance of anaemia in haemodialysis patients previously treated with epoetin. Presentation, XLV ERAEDTA Congress, Stockholm, 10- 13 May 2008.
10. Affymax: Affymax and Takeda announce phase 3 trials meet primary endpoints for investigational drug, Hematide(TM)/peginesatide, to treat anemia in chronic renal failure with some differences noted in secondary analyses (press release). www. investors.affymax.com/releasedetail. cfm?ReleaseID=481068 (last accessed 5 November 2010).
11. Bugelski PJ, Capocasale RJ, Makropoulos D, Marshall D, Fisher PW, Lu J, Achuthanandam R, Spinka- Doms T, Kwok D, Graden D, Volk A, Nesspor T, James IE, Huang C: CNTO 530:molecular pharmacology in human UT- 7EPO cells and pharmacokinetics and pharmacodynamics in mice. J Biotechnol 2008; 134(1- 2):171-180.
12. Sathyanarayana P, Houde E, Marshall D, Volk A, Makropoulos D, Emerson C, Pradeep A, Bugelski PJ, Wojchowski DM: CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools. Blood 2009;113:4955-4962.
13. Pérez- Ruixo JJ, Krzyzanski W, Bouman- Thio E, Miller B, Jang H, Bai SA, Zhou H, Yohrling J, Cohen A, Burggraaf J, Franson K, Davis HM: Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects. Clin Pharmacokinet 2009;48:601-613.
14. Bouman- Thio E, Franson K, Miller B, Getsy J, Cohen A, Bai SA, Yohrling J, Frederick B, Marciniak S, Jiao Q, Jang H, Davis H, Burggraaf J: A phase I, single and fractionated, ascendingdose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects. J Clin Pharmacol 2008;48: 1197-1207.
15. Sakai R, Miwa K, Eto Y: Local administration of activin promotes fracture healing in the rat fibula fracture model. Bone 1999;25:191-196. (Pubitemid 29317621)
16. Raje N, Vallet S: Sotatercept, a soluble activin receptor type 2A IgG- Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther 2010;12:586-597.
17. Shao L, Frigon NL, Young AL, Yu AL, Mathews LS, Vaughan J, Vale W, Yu J: Effect of activin A on globin gene expression in purified human erythroid progenitors. Blood 1992;79: 773-781.
18. Finberg KE, Whittlesey RL, Fleming MD, Andrews NC: Down- regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis. Blood 2010;115: 3817-3826.
19. Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R, Underwood KW, Seehra J, Yang Y, Condon CH, Sherman ML: Single- dose, randomized, double- blind, placebocontrolled study of ACE- 011 (ActRIIA- IgG1) in postmenopausal women. J Bone Miner Res 2009;24: 744-752.
20. Besarab A, Hulter HN, Klaus S, Lee TT, Lilienfeld DE, Neff TB, Piper BA, Provenzano R, Peony Yu KH: FG- 4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients (abstract SA- FC416). Renal Week Am Soc Nephrol, Denver, 16-21 November 2010.
21. Medical News Today: Akebia announces positive results for AKB- 6548 phase 1 clinical study. www.medicalnewstoday.com/ articles/175159.php (last accessed 7 March 2011).
22. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032.
23. Schwenk MH: Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease. Pharmacotherapy 2010;30: 70-79.
24. Lu M, Cohen MH, Rieves D, Pazdur R: FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol 2010;85:315-319.
25. Lyseng- Williamson KA, Keating GM: Ferric carboxymaltose: a review of its use in iron- deficiency anaemia. Drugs 2009;69:739-756.
26. Covic A, Mircescu G: The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi- centre, open- label, clinical study. Nephrol Dial Transplant 2010;25:2722-2730.
27. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD: A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non- dialysisdependent chronic kidney disease patients. Nephrol Dial Transplant 2010, E- pub ahead of print.
28. Mani LY, Nseir G, Venetz JP, Pascual M: Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient. Transplantation 2010;90:804-805.
29. Wikström B, Bhandari S, Barany P, Kalra PA, Ladefoged S, Wilske J, Thomsen LL: Iron isomaltoside 1000:a new intravenous iron for treating iron deficiency in chronic kidney disease. J Nephrol. 2011, E- pub ahead of print.